Early Precise Diagnosis and Intervention of CPT Based on a Noninvasive 3D-vHPS

Cirrhosis Clinical Trial

Official title: Early Precise Diagnosis and Intervention of Cirrhotic Portal Hypertension (CPT) Based on a Noninvasive 3D-virtual-model of Hepatic Portal System (3D-vHPS)

Status Active, not recruiting

Clinical Trial Summary

The aim of this study is to investigate the possibilities of early and precise management to decrease portal vein pressure in cirrhotic patients, guided by a non-invasive 3D-virtual-model of hepatic portal system (3D-vHPS). Healthy volunteers are enrolled to determine the normal range of pressure density in different sites of HPS. Cirrhotic patients without visible gastro-esophageal varies by endoscopy are randomly enrolled to virtual portal vein pressure gradient (vPVPG) monitored or non-vPVPG monitored groups. Non-vPVPG groups are followed-up and treated according to Baveno V consensus in portal hypertension. Patients in vPVPG-monitored groups are followed-up by anatomic computed tomographic angiography (CTA) and Doppler ultrasound every six months. Once vPVPG is above 12mm of mercury (Hg), participants will receive carvedilol treatment. All cirrhotic patients are followed-up with the incidence of portal hypertension-related complications, mortality rate and life quality assessment.

Clinical Trial Description

The non-invasive 3D-HPS is a newly-developed test to determine vPVPG based on anatomic computed tomographic angiography (CTA) and Doppler ultrasound. In this study, vPVPG is determined by the 3D-HPS. ;

Related Conditions & MeSH terms

• Cirrhosis
• Hypertension
• Hypertension, Portal
• Portal Hypertension

• NCT number: NCT02925975
• Study type: Interventional
• Source: Shanghai Tongji Hospital, Tongji University School of Medicine
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: January 2015
• Completion date: June 2020